14 Best Mid-Cap Growth Stocks to Buy Right Now

Page 12 of 13

2. Repligen Corporation (NASDAQ:RGEN)

Number of Hedge Fund Holders: 53

Repligen Corporation (NASDAQ:RGEN) is one of the best mid-cap growth stocks to buy right now. On January 16, UBS raised the firm’s price target on Repligen to $200 from $190, while maintaining a Buy rating. The firm believes that Repligen is uniquely positioned to lead a sustained recovery in the bioprocessing sector, supported by its diversified growth drivers and the accelerating reshoring trend. With over 20% order growth and an expanding footprint in Edge manufacturing, the firm sees Repligen as a core beneficiary as biopharma companies move production closer to their primary markets in 2026.

Additionally, previously on December 16, Repligen Corporation (NASDAQ:RGEN) announced the launch of three new high-performance chromatography resins: AVIPure HiPer AAV9, AVIPure HiPer AAV8 (affinity resins), and HiPer QA (anion exchange resin). These additions expand the company’s protein portfolio and are specifically designed to address the needs of next-gen bioprocessing, particularly for viral vectors used in gene therapy.

These resins use Tantti DuloCore base bead tech for convective flow. This engineering is intended to improve molecule stability, accelerate product development, and enhance overall process economics for gene therapy developers. By using both AVIPure affinity ligands and HiPer bead technologies, these tools offer faster processing times and performance for complex biotherapeutic workflows.

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Page 12 of 13